Replies to post #17519 on Biotech Values

[DewDiligence]

Re: IMCL

>is it perfectly logical that Erbitux be second-line (to chemo I presume), or is this a consequence of the clinical trial process in that it is difficult to displace the SoC due to ethical concerns<

It’s a consequence of the clinical data available to date. There are yet no completed pivotal studies for Erbitux in first-line CRC, although a large trial run by Merck KGaA is underway:

http://www.clinicaltrials.gov/ct/gui/show/NCT00154102

(This is the trial I just added to the clinical-trial / regulatory calendar at #msg-8263468.)

For the way on which Erbitux and Avastin are typically used in the different lines of colorectal-cancer treatment, please see #msg-8192287.